Delivery Order SPE2DB22D1106-SPE2DB25FFDZ6
- Not listed
- The Defense Logistics Agency awarded a $1,709.46 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 200 mg/1.14 mL syringes. The contract, which is a non-set-aside competitive award with firm fixed pricing, is scheduled for completion by August 12, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $47,704.56 delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Dupixent 300 mg/2 mL syringes. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 8, 2025, and represents a child order under AmerisourceBergen's larger contract vehicle with DLA. The pharmaceutical product will be delivered to AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $10,777.92 to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL syringes on July 18, 2025, with completion scheduled for July 21, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $17,017.67 to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Dupixent 300 mg/2 mL syringes. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's headquarters location...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,709.46 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL syringes on July 26, 2025, with an ultimate completion date of July 28, 2025. This firm fixed price contract represents a non-competitive set-aside order placed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999. The order will be fulfilled from...
- The Defense Logistics Agency awarded a delivery order valued at $20,513.52 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL syringes on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside transaction for pharmaceutical supply to support federal medical procurement needs. The contract is executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a $17,652.82 delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Dupixent 300 mg/2 mL syringes. This is a firm fixed price, non-set-aside contract with an ultimate completion date of August 20, 2025, with performance at the vendor's location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion...
- The Defense Logistics Agency awarded a $31,152.11 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Dupixent 200 mg/1.14 mL syringes with a completion date of August 5, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $17,094.60 to AmerisourceBergen Drug Corp for the supply of Dupixent 200 mg/1.14 ml syringes on August 4, 2025, with an ultimate completion date of August 5, 2025. The contract utilizes firm fixed pricing and carries no set-aside designation, indicating it was competitively awarded. The place of performance is listed as Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate headquarters. This delivery order is...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for Dupixent 300mg/2ml syringes valued at $44,390.30. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 20, 2025, with performance at the contractor's corporate office location in Conshohocken, Pennsylvania. The award does not utilize a set-aside designation and represents a child contract under AmerisourceBergen's...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFDZ6Delivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $3,470.16 delivery order on August 19, 2025, for the supply of Dupixent 200 mg/1.14 mL syringes with an ultimate completion date of August 20, 2025. This firm fixed-price contract, which involves no set-aside designation, is positioned under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion pharmaceutical prime vendor agreement extending through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a routine pharmaceutical procurement supporting the Defense Health Agency and broader federal military healthcare systems. AmerisourceBergen, a major pharmaceutical distributor and critical vendor for federal medical procurement, maintains extensive federal contract authority to supply brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. The company's IDC vehicle enables flexible pharmaceutical sourcing for military healthcare programs worldwide, and this particular order for Dupixent—a specialty biologic used in treating conditions such as atopic dermatitis and asthma—exemplifies the type of brand-name specialty medication typically procured through the DLA's pharmaceutical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 8/19/25 |